A Randomized Trial of Aerobic Exercise and Sleep Quality in Lymphoma Patients Receiving Chemotherapy or No Treatments
A Randomized Trial of Aerobic Exercise and Sleep Quality in Lymphoma Patients Receiving Chemotherapy or No Treatments
复制标题
DOI：
10.1158/1055-9965.epi-12-0075
复制
发表时间：
2012-06-01
影响因子：
3.8
通讯作者：
Reiman, Tony
中科院分区：
文献类型：
--
作者：
Courneya, Kerry S.;Sellar, Christopher M.;Reiman, Tony
背景：淋巴瘤患者存在睡眠问题，可以通过有氧运动来解决，但之前没有研究探讨过这个问题。方法：我们将 122 名淋巴瘤患者随机分为常规护理 (n = 62) 或 12 周监督有氧运动训练 (AET；n = 60)。我们的主要睡眠终点是通过匹兹堡睡眠质量指数 (PSQI) 评估的全球睡眠质量。次要终点是 PSQI 成分分数。还进行了计划的亚组分析。结果：意向治疗分析表明，与常规护理相比，AET 导致整体睡眠质量无显着改善（P = 0.16）[平均组间差异 = -0.64； 95% 置信区间 (Cl)，-1.56 至 +0.27]。在计划的亚组分析中，在淋巴瘤类型（P-相互作用= 0.006）、当前治疗状态（P-相互作用= 0.036）、诊断后时间（P-相互作用= 0.010）、体重指数（P-相互作用= 0.075）和基线睡眠质量（P-相互作用= 0.041）方面确定了统计显着或临界显着的相互作用。具体而言，AET 改善了患有惰性非霍奇金淋巴瘤 (P = 0.001)、正在接受化疗 (P = 0.013)、正在接受化疗 (P = 0.013) 的淋巴瘤患者的整体睡眠质量。
Background: Patients with lymphoma experience sleep problems that may be managed with aerobic exercise but no previous study has examined this issue.Methods: We randomized 122 patients with lymphoma to usual care (n = 62) or 12 weeks of supervised aerobic exercise training (AET; n = 60). Our primary sleep endpoint was global sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI). Secondary endpoints were the PSQI component scores. Planned subgroup analyses were also conducted.Results: Intention-to-treat analyses indicated that AET resulted in a nonsignificant (P = 0.16) improvement in global sleep quality compared with usual care [mean group difference = -0.64; 95% confidence interval (Cl), -1.56 to +0.27]. In planned subgroup analyses, statistically significant or borderline significant interactions were identified for type of lymphoma (P-interaction = 0.006), current treatment status (P-interaction = 0.036), time since diagnosis (P-interaction = 0.010), body mass index (P-interaction = 0.075), and baseline sleep quality (P-interaction = 0.041). Specifically, AET improved global sleep quality in patients with lymphoma who had indolent non-Hodgkin lymphoma (P = 0.001), were receiving chemotherapy (P = 0.013), were